Is Ascendis Pharma Stock a Good Investment?
Ascendis Pharma Investment Advice | ASND |
- Examine Ascendis Pharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Ascendis Pharma's leadership team and their track record. Good management can help Ascendis Pharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Ascendis Pharma's business and its evolving consumer preferences.
- Compare Ascendis Pharma's performance and market position to its competitors. Analyze how Ascendis Pharma is positioned in terms of product offerings, innovation, and market share.
- Check if Ascendis Pharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Ascendis Pharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Ascendis Pharma AS stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Ascendis Pharma AS is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Ascendis Pharma Stock
Researching Ascendis Pharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 99.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 7.81. Ascendis Pharma AS had not issued any dividends in recent years.
To determine if Ascendis Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Ascendis Pharma's research are outlined below:
| Ascendis Pharma AS generated a negative expected return over the last 90 days | |
| Ascendis Pharma AS has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 266.72 M. Net Loss for the year was (481.45 M) with profit before overhead, payroll, taxes, and interest of 39.04 M. | |
| Ascendis Pharma AS currently holds about 955.15 M in cash with (467.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 17.11. | |
| Ascendis Pharma AS has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are held by institutions such as insurance companies |
Ascendis Pharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Ascendis Pharma AS. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ascendis Pharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 15th of February 2024 Upcoming Quarterly Report | View | |
| 25th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Ascendis Pharma's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 7.76 B.Ascendis Pharma's profitablity analysis
The company has Profit Margin (PM) of (1.54) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (3.7) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $3.7.Determining Ascendis Pharma's profitability involves analyzing its financial statements and using various financial metrics to determine if Ascendis Pharma is a good buy. For example, gross profit margin measures Ascendis Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Ascendis Pharma's profitability and make more informed investment decisions.
Please note, the presentation of Ascendis Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ascendis Pharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Ascendis Pharma's management manipulating its earnings.
Basic technical analysis of Ascendis Stock
As of the 25th of November, Ascendis Pharma shows the mean deviation of 2.09, and Risk Adjusted Performance of (0). Ascendis Pharma AS technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Ascendis Pharma AS standard deviation, as well as the relationship between the maximum drawdown and kurtosis to decide if Ascendis Pharma AS is priced correctly, providing market reflects its regular price of 129.81 per share. Given that Ascendis Pharma has information ratio of (0.05), we suggest you to validate Ascendis Pharma AS's prevailing market performance to make sure the company can sustain itself at a future point.Ascendis Pharma's Outstanding Corporate Bonds
Ascendis Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ascendis Pharma AS uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ascendis bonds can be classified according to their maturity, which is the date when Ascendis Pharma AS has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| ASCENSION HEALTH Corp BondUS04352EAA38 | View | |
| US04352EAB11 Corp BondUS04352EAB11 | View | |
| ASCENSION HEALTH ALLIANCE Corp BondUS04351LAB62 | View | |
| US04351LAA89 Corp BondUS04351LAA89 | View |
Understand Ascendis Pharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Ascendis Pharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0) | |||
| Market Risk Adjusted Performance | (0.06) | |||
| Mean Deviation | 2.09 | |||
| Coefficient Of Variation | (6,614) | |||
| Standard Deviation | 3.35 | |||
| Variance | 11.25 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.17) | |||
| Total Risk Alpha | (0.59) | |||
| Treynor Ratio | (0.07) | |||
| Maximum Drawdown | 22.16 | |||
| Value At Risk | (3.56) | |||
| Potential Upside | 4.75 | |||
| Skewness | 1.66 | |||
| Kurtosis | 11.49 |
| Risk Adjusted Performance | (0) | |||
| Market Risk Adjusted Performance | (0.06) | |||
| Mean Deviation | 2.09 | |||
| Coefficient Of Variation | (6,614) | |||
| Standard Deviation | 3.35 | |||
| Variance | 11.25 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.17) | |||
| Total Risk Alpha | (0.59) | |||
| Treynor Ratio | (0.07) | |||
| Maximum Drawdown | 22.16 | |||
| Value At Risk | (3.56) | |||
| Potential Upside | 4.75 | |||
| Skewness | 1.66 | |||
| Kurtosis | 11.49 |
Consider Ascendis Pharma's intraday indicators
Ascendis Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Ascendis Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Ascendis Pharma time-series forecasting models is one of many Ascendis Pharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ascendis Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Ascendis Stock media impact
Far too much social signal, news, headlines, and media speculation about Ascendis Pharma that are available to investors today. That information is available publicly through Ascendis media outlets and privately through word of mouth or via Ascendis internal channels. However, regardless of the origin, that massive amount of Ascendis data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Ascendis Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Ascendis Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Ascendis Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Ascendis Pharma alpha.
Ascendis Pharma Corporate Management
| Michael LLM | Chief VP | Profile | |
| Birgitte MD | Sr Affairs | Profile | |
| Stina MD | Executive Oncology | Profile | |
| Scott Holmes | Head Endocrinology | Profile | |
| Timothy Lee | Director Relations | Profile | |
| Nyssa Noyola | Vice Management | Profile | |
| Jens Okkels | VP Devel | Profile |
Already Invested in Ascendis Pharma AS?
The danger of trading Ascendis Pharma AS is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Ascendis Pharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Ascendis Pharma. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Ascendis Pharma AS is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Ascendis Pharma AS is a strong investment it is important to analyze Ascendis Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascendis Pharma's future performance. For an informed investment choice regarding Ascendis Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascendis Pharma AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ascendis Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Ascendis Pharma AS is measured differently than its book value, which is the value of Ascendis that is recorded on the company's balance sheet. Investors also form their own opinion of Ascendis Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascendis Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ascendis Pharma's market value can be influenced by many factors that don't directly affect Ascendis Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Ascendis Pharma's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Ascendis Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ascendis Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.